Aminaftone is used for its ability to downregulate endothelin-1 (ET-1) production by interfering with the transcription of the pre-pro-ET-1 (PPET-1) gene; it inhibits ET-1 production in cell cultures in a concentration-dependent manner without affecting endothelin-converting enzyme (ECE) activity; in vivo, it reduces plasma ET-1 levels, attenuates right heart hypertrophy, decreases pulmonary artery wall thickness, and significantly lowers mortality in monocrotaline-induced pulmonary hypertension models in rats.